Respirerx Pharmaceuticals Stock Gross Profit
| RSPIDelisted Stock | USD 0.01 0.00 0.00% |
RespireRx Pharmaceuticals fundamentals help investors to digest information that contributes to RespireRx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of RespireRx Pink Sheet. The fundamental analysis module provides a way to measure RespireRx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to RespireRx Pharmaceuticals pink sheet.
RespireRx |
RespireRx Pharmaceuticals Company Gross Profit Analysis
RespireRx Pharmaceuticals' Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, RespireRx Pharmaceuticals reported 0.0 of gross profit. This is 100.0% lower than that of the Pharmaceuticals sector and 100.0% lower than that of the Health Care industry. The gross profit for all United States stocks is 100.0% higher than that of the company.
RespireRx Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses RespireRx Pharmaceuticals' direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of RespireRx Pharmaceuticals could also be used in its relative valuation, which is a method of valuing RespireRx Pharmaceuticals by comparing valuation metrics of similar companies.RespireRx Pharmaceuticals is currently under evaluation in gross profit category among its peers.
RespireRx Fundamentals
| Return On Asset | -8.34 | ||||
| Current Valuation | 3.18 M | ||||
| Shares Outstanding | 119.59 M | ||||
| Shares Owned By Insiders | 20.63 % | ||||
| Number Of Shares Shorted | 126 | ||||
| Price To Earning | (0.25) X | ||||
| Price To Sales | 1,051 X | ||||
| EBITDA | (2.42 M) | ||||
| Net Income | (3.14 M) | ||||
| Cash And Equivalents | 21 | ||||
| Total Debt | 2.42 M | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0.1) X | ||||
| Cash Flow From Operations | (956.17 K) | ||||
| Short Ratio | 1.47 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Target Price | 0.3 | ||||
| Beta | 0.24 | ||||
| Market Capitalization | 837.16 K | ||||
| Total Asset | 208.74 K | ||||
| Retained Earnings | (156.09 M) | ||||
| Working Capital | (4.89 M) | ||||
| Current Asset | 157 K | ||||
| Current Liabilities | 5.05 M | ||||
| Net Asset | 208.74 K |
About RespireRx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze RespireRx Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of RespireRx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of RespireRx Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in RespireRx Pink Sheet
If you are still planning to invest in RespireRx Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the RespireRx Pharmaceuticals' history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |